Search terms
Results 1 - 1 of 1 - ordered by :

Bivalirudin is shown to be superior to abciximab in reducing the net adverse clinical events and major bleeding in STEMI in the HORIZONS-AMI trial (Stone et al NEJM, 2008). After excluding patients ...

Heart, BCS Abstracts 2011, R Showkathali, J Davies, N Malik, W Taggu, J Sayer, R Aggarwal, P Kelly

Date : 01/06/2011